The contract manufacturing market for Pharmaceuticals in China is estimated to be worth USD 13 billion in 2030
Owing to reasons,such as a booming economy and availability of skilled labor, outsourcing toAsian CMOs, primarily in China, is considered an attractive business model topharmaceutical developers / sponsors, across the world
Roots Analysis is pleased toannounce the publication of its recent study, titled, “ChinaPharmaceutical Contract Manufacturing Services Market, 2020-2030.”
The report features an extensive study of thecurrent market landscape and future opportunities associated with thepharmaceutical contract manufacturing market in China. The study also featuresa detailed analysis, highlighting the capabilities of pharmaceutical CMOs inthis region. Amongst other elements, the report features:
§ A detailed assessmentof the current market landscape of pharmaceutical contract manufacturers inChina engaged in the development of active pharmaceutical ingredients (APIs),intermediates and finished dosage formulations (FDFs).
§ A detailed landscapeof the pharmaceutical manufacturing facilities in China, including an analysisbased on location of these facilities, highlighting key manufacturing hubs.
§ A brief discussion ofvarious regulatory guidelines in China and various challenges, related toregulatory scrutiny, faced by pharmaceutical manufacturers in China.
§ Detailed profiles of keyplayers that offer a diverse range of capabilities for the manufacturing ofpharmaceutical products in China.
§ A review of the pharmaceuticalmanufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019by revenues).
§ An analysis of thepartnerships and acquisitions that have been established in this domain, in therecent past.
§ A detailed capacityanalysis based on the installed reactor capacities of the manufacturingfacilities in China.
§ A case studycomparing the key characteristics of large molecule and small molecule drugs,along with details on the various steps involved in their respectivemanufacturing processes.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
§ Key GeographicalRegions
- Eastern China
- Southern China
- Northern China
§ Type of Product
- Active Pharmaceutical Ingredients (APIs)
- Drug Products
§ Type of Drug Product
- Solid
- Liquid / Semi-Solid
- Injectable
- Others
§ Scale of Operation
- Clinical
- Commercial
§ Company Size
- Small
- Mid-Sized
- Large / Very Large
Keyplayers covered in the report
§ 2Y-Chem
§ Aurisco Pharmaceutical
§ ChemPartner
§ Dorrapharma
§ Hubei Biocause Pharmaceutical
§ Infoark
§ Ningbo Menovo Pharmaceutical
§ Shandong Xinhua Pharmaceutical
§ Shanghai Acebright Pharmaceuticals
§ STA Pharmaceutical
§ Zhejiang Huahai Pharmaceutical
For more information pleaseclick on the following
Other RecentOfferings
1. ChinaBiopharmaceutical Contract ManufacturingMarket, 2020 – 2030
2. HPAPIand Cytotoxic Drugs ManufacturingMarket (3rd Edition), 2020-2030
3. Novelcoronavirus (COVID-19): Preventive Vaccines,Therapeutics and Diagnostics in Development
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
